ENHANCING SHAREHOLDER VALUE THROUGH EXCEPTIONAL BUSINESS PERFORMANCE AND PRACTICES, AND THROUGH RESPONSIBLE AND EFFECTIVE COMMUNICATION WITH ITS SHAREHOLDERS.
Hoth Therapeutics is a development stage biopharmaceutical company focused on proprietary therapeutics for Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH’s pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth recently entered into a Joint Development Agreement to further the development of vaccine prospects to prevent, intercept or treat the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH).
Keep up to date on Hoth Therapeutics News. Simply fill out your
email below and you will be added to our email newsletter.